touchCONGRESS

Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Multiple Myeloma Watch Time: 64 mins

touchCONGRESS Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021

Watch this two-part activity exploring recent data for BCMA-targeting agents in multiple myeloma. Filmed following the European Hematology Association 2021 Virtual Congress.

Part 1: Watch multiple myeloma expert Dr María-Victoria Mateos review key data from the EHA2021 Virtual Congress Watch Now
Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

 

  • Part 1: Data Review
Next Chapter
Introduction
BCMA-targeting CAR T-cell therapies in relapsed/refractory multiple myeloma
BCMA-targeting antibody–drug conjugates in relapsed/refractory multiple myeloma
BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma
Video Player Controls:
 
Leave Feedback
Overview

Watch Dr María-Victoria Mateos summarize and share her interpretation of the latest data from the EHA2021 Virtual Congress on the use of BCMA-targeting therapy for the management of relapsed/refractory multiple myeloma. During the presentation she considers:

  • BCMA-targeting CAR T-cell therapies in relapsed/refractory multiple myeloma
  • BCMA-targeting antibody–drug conjugates in relapsed/refractory multiple myeloma
  • BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma
About Dr María-Victoria Mateos

María-Victoria Mateos is a Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. read more

She is the Director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Haematology Department.

Dr Mateos serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials in elderly patients and patients with smouldering myeloma, which have profoundly influenced current options for treating these patient populations.

Dr Mateos is also a member of the International Myeloma Working Group (IMWG), the International Myeloma Society (IMS), EHA and the American Society of Hematology (ASH). She has published over 200 papers in peer-reviewed international journals, some of which have become key references in the multiple myeloma field. Since 2011, she has been Associate Editor of myeloma in Annals of Haematology and she has acted as a reviewer for top journals such as the New England Journal of Medicine, the Lancet and Lancet Oncology.

Dr Mateos served on the EHA Scientific Program Committee and Advisory Board from 2013 to 2017, and on the ASH Scientific Committee on plasma cell diseases from 2015 to 2017.

Dr María-Victoria Mateos discloses: Advisory Board or panel fees from Abbvie, Adaptive, Amgen, Celgene, GlaxoSmithKline, Genentech, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda. Speaker’s Bureau fees from Amgen, Celgene, GlaxoSmithKline, Janssen and Takeda.

Downloads

View and download resources from this activity to support your learning or share with colleagues

  • Part 2: Expert Interviews
Leave Feedback
Dr María-Victoria Mateos
Watch Time: 08:57
University of Salamanca, Salamanca, Spain

María-Victoria Mateos considers the latest data on BCMA-targeting agents for the management of relapsed/refractory multiple myeloma from the EHA2021 Virtual Congress.

 
 
Leave Feedback
Interview Questions

In this interview María-Victoria Mateos answers the following questions:

  • How do the updated results from the KarMMa and CARTITUDE-1 trials add to our knowledge of CAR T-cell therapy in relapsed/refractory multiple myeloma?
  • What adverse events associated with CAR T-cell therapies do healthcare professionals need to be aware of and do data presented at EHA2021 Virtual shed any light on their management in clinical practice?
  • What do the analyses from DREAMM-2, exploring ocular toxicities associated with belantamab mafodotin, mean for clinical practice?
  • What are the key learnings from clinical trials of bispecific antibodies presented at EHA2021 Virtual and how will they influence treatment of multiple myeloma in the future?
  • Based on presentations at EHA2021 Virtual, how do you think the role of BCMA-targeting therapies in the treatment of multiple myeloma will evolve in the future?
About Dr María-Victoria Mateos

María-Victoria Mateos is a Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. read more

She is the Director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Haematology Department.

Dr Mateos serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials in elderly and smouldering myeloma patients that have profoundly influenced current options for treating these patient populations.

Dr Mateos is also a member of the International Myeloma Working Group (IMWG), the International Myeloma Society (IMS), EHA and the American Society of Hematology (ASH). She has published over 200 papers in peer-reviewed international journals, some of which have become key references in the multiple myeloma field. Since 2011, she has been Associate Editor of myeloma in Annals of Haematology and she has acted as a reviewer for top journals such as the New England Journal of Medicine, the Lancet and Lancet Oncology.

Dr Mateos served on the EHA Scientific Program Committee and Advisory Board from 2013 to 2017, and on the ASH Scientific Committee on plasma cell diseases from 2015 to 2017.

Dr María-Victoria Mateos discloses: Advisory Board or panel fees from Abbvie, Adaptive, Amgen, Celgene, GlaxoSmithKline, Genentech, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda. Speaker’s Bureau fees from Amgen, Celgene, GlaxoSmithKline, Janssen and Takeda.

Dr Heather Sutherland
Watch Time: 15:28
Vancouver General Hospital, Vancouver, BC, Canada

Heather Sutherland considers the latest data on BCMA-targeting agents for the management of relapsed/refractory multiple myeloma from the EHA2021 Virtual Congress.

 
Leave Feedback
Interview Questions

In this interview Heather Sutherland answers the following questions:

  • How do the updated results from the KarMMa and CARTITUDE-1 trials add to our knowledge of CAR T-cell therapy in relapsed/refractory multiple myeloma?
  • What adverse events associated with CAR T-cell therapies do healthcare professionals need to be aware of and do data presented at EHA2021 Virtual shed any light on their management in clinical practice?
  • What do the analyses from DREAMM-2, exploring ocular toxicities associated with belantamab mafodotin, mean for clinical practice?
  • What are the key learnings from clinical trials of bispecific antibodies presented at EHA2021 Virtual and how will they influence treatment of multiple myeloma in the future?
  • Based on presentations at EHA2021 Virtual, how do you think the role of BCMA-targeting therapies in the treatment of multiple myeloma will evolve in the future?
About Dr Heather Sutherland

Heather Sutherland has been a Staff Physician at the Vancouver General Hospital since 1990 and an Attending Leukaemia and Bone Marrow Transplant Staff Physician since 1991. Her clinical practice is now exclusively in this area with a focus on the treatment of patients with multiple myeloma. She is also Clinical Professor at the University of British Columbia. read more

Dr Sutherland has been a member of the Research Ethics Board of BC Cancer Agency and University of British Columbia since 2014. She was Associate Editor of Cytotherapy from 1999 to 2010 and has acted as a reviewer for journals such as Blood, the Journal of Hematology and Leukemia and Lymphoma.

Dr Sutherland has a special interest in clinical trials of new myeloma therapies and in the development of novel therapies for multiple myeloma in the laboratory. She has been principal investigator on several clinical trials and has published over 100 original papers in international journals. Her areas of interest include multiple myeloma, the biology of plasma cells and the development of new drugs.

Dr Heather Sutherland discloses: Advisory Board fees from Amgen, Bristol Myers Squibb, Janssen Sanofi and Takeda. Research funding from GlaxoSmithKline, Janssen and Karyopharm.

Prof. Dr. Niels van de Donk
Watch Time: 14:13
Amsterdam University Medical Center, Amsterdam, The Netherlands

Niels van de Donk considers the latest data on BCMA-targeting agents for the management of relapsed/refractory multiple myeloma from the EHA2021 Virtual Congress.

 
 
Leave Feedback
Interview Questions

In this interview Niels van de Donk answers the following questions:

  • How do the updated results from the KarMMa and CARTITUDE-1 trials add to our knowledge of CAR T-cell therapy in relapsed/refractory multiple myeloma?
  • What adverse events associated with CAR T-cell therapies do healthcare professionals need to be aware of and do data presented at EHA2021 Virtual shed any light on their management in clinical practice?
  • What do the analyses from DREAMM-2, exploring ocular toxicities associated with belantamab mafodotin, mean for clinical practice?
  • What are the key learnings from clinical trials of bispecific antibodies presented at EHA2021 Virtual and how will they influence treatment of multiple myeloma in the future?
  • Based on presentations at EHA2021 Virtual, how do you think the role of BCMA-targeting therapies in the treatment of multiple myeloma will evolve in the future?
About Prof. Dr. Niels van de Donk

Niels van de Donk is a Haematologist at Amsterdam University Medical Center, where he was appointed as full professor in February 2020. He specializes in haematology at the University Medical Center Utrecht. read more

Following a fellowship at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute in Boston, MA, USA, he assumed his current post in Amsterdam.

Prof. Dr. van de Donk’s special interest is the treatment of patients with multiple myeloma. He is the principal investigator of several investigator-initiated studies. Furthermore, he is involved in translational research aiming to find new targets for therapy, with a focus on immune therapy.

He is author or co-author of a number of books and many papers published in peer-reviewed journals. He is also secretary of the Heamato Oncology Foundation for Adults in the Netherlands (HOVON) multiple myeloma working party and scientific secretary of the European Myeloma Network. He has served on the EHA Scientific Program Committee since 2018.

Prof. Dr. Niels van de Donk discloses: Advisory Board fees from Adaptive, Amgen, Bayer, Bristol Myers Squibb, Celgene, Janssen Pharmaceuticals, Novartis, Roche, Servier and Takeda. Research support from Amgen, Bristol Myers Squibb, Celgene, Cellectis, Janssen and Novartis.

Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview

Stay up to date with the latest data for BCMA-targeting agents in the treatment of multiple myeloma in this two-part activity. Filmed following the EHA2021 Virtual Congress.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall efficacy data for BCMA-targeting agents in the treatment of multiple myeloma
  • Describe the safety data for BCMA-targeting agents in the treatment of multiple myeloma
  • Discuss how the latest data on BCMA-targeting agents may affect the management of patients with multiple myeloma
Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions.
  • Interactive CME and e-learning modules.
  • Video conference highlights.
Register For Free Now

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72